Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.69 |
| ▸ | HTRA1 | Q92743 | 2/20 | 0.66 |
| ▸ | CTSL | P07711 | 4/20 | 0.65 |
| ▸ | CTSS | P25774 | 3/20 | 0.65 |
| ▸ | CTSB | P07858 | 2/20 | 0.65 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.62 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13933719 | 1.00 | CTSK (0.69) | CTSKHTRA1CTSLCTSSCTSB | |
| SCHEMBL14539102 | 1.00 | CTSK (0.69) | CTSKHTRA1CTSLCTSSCTSB | |
| SCHEMBL13890323 | 0.99 | CTSK (0.70) | CTSKHTRA1CTSLCTSSCTSB | |
| SCHEMBL8255445 | 0.93 | HTRA1 (0.67) | CTSKHTRA1CTSLCTSSCTSB | |
| SCHEMBL2256230 | 0.93 | HTRA1 (0.67) | CTSKHTRA1CTSLCTSSCTSB | |
| SCHEMBL8261580 | 0.92 | CTSK (0.67) | CTSKHTRA1CTSLCTSSCTSB | |
| SCHEMBL2253423 | 0.92 | CTSK (0.67) | CTSKHTRA1CTSLCTSSCTSB | |
| SCHEMBL14091680 | 0.91 | CTSK (0.69) | CTSKHTRA1CTSLCTSSCTSB | |
| SCHEMBL8261559 | 0.88 | CTSK (0.64) | CTSKHTRA1CTSLCTSSCTSB | |
| SCHEMBL2251232 | 0.88 | CTSK (0.64) | CTSKHTRA1CTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118183195-B | Bidirectional logistics carriage conveying system and energy-saving operation control method thereof | 北京物资学院 | 2026-05-12 | — | — | CN | claimed |
| EP-4476217-A1 | MORPHIC FORMS OF CFT7455 AND METHODS OF MANUFACTURE THEREOF | C4 Therapeutics, Inc. (US) | 2024-12-18 | — | — | EP | claimed |
| CN-118660884-A | Crystal form of CFT7455 and method for producing same | C4医药公司 | 2024-09-17 | — | — | CN | claimed |
| US-20240294986-A1 | PRECISION MEDICINE FOR SCHIZOPHRENIA AND PSYCHOTIC DISORDERS: OBJECTIVE ASSESSMENT, RISK PREDICTION, PHARMACOGENOMICS, AND REPURPOSED DRUGS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2024-09-05 | — | — | US | claimed |
| EP-4355423-A1 | PRECISION MEDICINE FOR SCHIZOPHRENIA AND PSYCHOTIC DISORDERS: OBJECTIVE ASSESSMENT, RISK PREDICTION, PHARMACOGENOMICS, AND REPURPOSED DRUGS | Indiana University Research and Technology Corporation (US) | 2024-04-24 | — | — | EP | claimed |
| EP-4313144-A1 | COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME | Angiex, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117355333-A | Combination comprising anti-TM 4SF1 antibody and immunotherapeutic agent and method of use thereof | 安吉克公司 | 2024-01-05 | — | — | CN | claimed |
| US-20230293713-A1 | ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME | ANGIEX, INC. | 2023-09-21 | — | — | US | claimed |
| WO-2023154417-A1 | MORPHIC FORMS OF CFT7455 AND METHODS OF MANUFACTURE THEREOF | C4 THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| EP-4192450-A1 | ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS | C4 Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | claimed |
| CN-116194438-A | Advantageous treatment of Ikaros or Aiolos mediated disorders | C4医药公司 | 2023-05-30 | — | — | CN | claimed |
| US-20220403469-A1 | Precision Medicine for Schizophrenia and Psychotic Disorders: Objective Assessment, Risk Prediction, Pharmacogenomics, and Repurposed Drugs | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-12-22 | — | — | US | claimed |
| US-20220340908-A1 | METHODS FOR DEPLETION OF DELETERIOUS MITOCHONDRIAL GENOMES | UNIVERSITY OF MASSACHUSETTS | 2022-10-27 | — | — | US | claimed |
| US-11466252-B2 | Expansion and differentiation of inner ear supporting cells and methods of use thereof | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2022-10-11 | — | — | US | claimed |
| WO-2022204565-A1 | COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME | ANGIEX, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| EP-4034168-A1 | METHODS FOR DEPLETION OF DELETERIOUS MITOCHONDRIAL GENOMES | University Of Massachusetts (US) | 2022-08-03 | — | — | EP | claimed |
| WO-2022032132-A1 | ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | claimed |
| US-20260117185-A1 | ENHANCEMENT OF FIBROBLAST PLASTICITY FOR TREATMENT OF DISC DEGENERATION | SPINALCYTE, LLC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20070282100-A1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070282100-A1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282100-A1 | Boronic ester and acid compounds, synthesis and uses | BCL6, BCAP31, CD79B | CTSK 2510/4885HTRA1 4673/4885CTSL 3805/4885 |
| US-20260117185-A1 | ENHANCEMENT OF FIBROBLAST PLASTICITY FOR TREATMENT OF DISC DEGENERATION | HDAC3, HDAC4, GSK3B | CTSK 1300/4885HTRA1 678/4885CTSL 712/4885 |
| US-20230293713-A1 | ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME | TM9SF4, TM9SF2, TM9SF3 | CTSK 1456/4885HTRA1 1618/4885CTSL 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.